Picroside II Improves Severe Acute Pancreatitis-Induced Intestinal Barrier Injury by Inactivating Oxidative and Inflammatory TLR4-Dependent PI3K/AKT/NF-
Animals
Cinnamates
/ pharmacology
Female
Gastrointestinal Microbiome
/ drug effects
Humans
Iridoid Glucosides
/ pharmacology
Male
Pancreatitis
/ drug therapy
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Rats
Rats, Sprague-Dawley
Signal Transduction
Toll-Like Receptor 4
/ drug effects
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
02
2020
accepted:
25
03
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
5
2
2021
Statut:
epublish
Résumé
Picroside II exerts anti-inflammatory and antidiarrheal effects for treating the diseases associated with oxidative injury. However, its function on pancreatitis-induced intestinal barrier injury remains unclear. SEM showed that intestinal barrier injury was caused with the loss of intestinal villi and mitochondria destruction, and pathological scores were increased in the MG group. The levels of amylase, lipase, malondialdehyde, TNF Picroside II improved the SAP-induced intestinal barrier injury in the rat model by inactivating oxidant and inflammatory signaling and improving gut microbiota.
Sections du résumé
BACKGROUND
BACKGROUND
Picroside II exerts anti-inflammatory and antidiarrheal effects for treating the diseases associated with oxidative injury. However, its function on pancreatitis-induced intestinal barrier injury remains unclear.
RESULTS
RESULTS
SEM showed that intestinal barrier injury was caused with the loss of intestinal villi and mitochondria destruction, and pathological scores were increased in the MG group. The levels of amylase, lipase, malondialdehyde, TNF
CONCLUSIONS
CONCLUSIONS
Picroside II improved the SAP-induced intestinal barrier injury in the rat model by inactivating oxidant and inflammatory signaling and improving gut microbiota.
Identifiants
pubmed: 32351672
doi: 10.1155/2020/3589497
pmc: PMC7174951
doi:
Substances chimiques
Cinnamates
0
Iridoid Glucosides
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
picroside II
39012-20-9
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3589497Informations de copyright
Copyright © 2020 Xuehua Piao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Pharmacol Res. 2020 Feb;152:104603
pubmed: 31863867
Neurochem Res. 2018 May;43(5):1058-1066
pubmed: 29671236
Mediators Inflamm. 2015;2015:685043
pubmed: 25878401
Biomed Pharmacother. 2018 Sep;105:599-605
pubmed: 29890468
J Gastrointest Surg. 2003 Jan;7(1):26-36
pubmed: 12559182
World J Gastroenterol. 2015 Apr 21;21(15):4555-63
pubmed: 25914464
J Clin Gastroenterol. 2012 Oct;46 Suppl:S46-51
pubmed: 22955357
Clin Exp Immunol. 2013 Jun;172(3):417-26
pubmed: 23600830
J Inflamm Res. 2018 Mar 09;11:77-85
pubmed: 29563826
BMC Vet Res. 2020 Feb 7;16(1):47
pubmed: 32028947
Int Immunopharmacol. 2018 Nov;64:140-150
pubmed: 30173054
Scand J Gastroenterol. 1980;15(8):1027-31
pubmed: 6165066
Inflammation. 2019 Dec;42(6):2129-2138
pubmed: 31605249
J Endocrinol. 2009 Mar;200(3):347-55
pubmed: 19066289
Cell Rep. 2019 Apr 16;27(3):750-761.e7
pubmed: 30995474
PLoS One. 2017 Apr 7;12(4):e0174414
pubmed: 28388666
Oxid Med Cell Longev. 2017;2017:7085709
pubmed: 28713490
Int J Mol Med. 2017 Jan;39(1):113-125
pubmed: 27878246
Pancreatology. 2019 Jan;19(1):158-162
pubmed: 30551934
Food Funct. 2020 Jan 29;11(1):153-162
pubmed: 31829366
Acta Pharmacol Sin. 2018 Sep;39(9):1439-1452
pubmed: 29671417
Am J Chin Med. 2007;35(4):681-91
pubmed: 17708634
Int Immunopharmacol. 2017 Oct;51:17-24
pubmed: 28759809
Acad Forensic Pathol. 2018 Jun;8(2):311-323
pubmed: 31240044
Burns. 2020 Jan 31;:
pubmed: 32014349
Hepatobiliary Pancreat Dis Int. 2017 Apr;16(2):155-159
pubmed: 28381378
J Cell Physiol. 2020 Jun;235(6):5041-5049
pubmed: 31898324
Exp Ther Med. 2015 Apr;9(4):1253-1258
pubmed: 25780418